Literature DB >> 23575206

Sarcopenia or muscle modifications in neurologic diseases: a lexical or patophysiological difference?

S Carda1, C Cisari, M Invernizzi.   

Abstract

Sarcopenia is a condition characterized by a decrease in muscle mass and function (strength and mobility) that is frequently observed in the elderly. In people with paresis and altered mobility due to central nervous system (CNS) diseases, this definition then may not be applicable. In CNS diseases, mainly stroke and spinal cord injury, different and specific patterns of muscle loss and muscle changes have been described, due to denervation, disuse atrophy, spasticity and myosteatosis. The main observations available about these phenomena in CNS diseases are reviewed, and a broad view on the specific physiopathological mechanisms is also described. Moreover, a description of the potential pharmacological targets and treatment strategies (physical and nutritional) is provided. Since sarcopenia of the elderly and muscle modifications and muscle atrophy in CNS diseases have different mechanisms, it is probable that they do not respond equally to the same treatments.

Entities:  

Mesh:

Year:  2013        PMID: 23575206

Source DB:  PubMed          Journal:  Eur J Phys Rehabil Med        ISSN: 1973-9087            Impact factor:   2.874


  12 in total

1.  Evaluation of serum myostatin and sclerostin levels in chronic spinal cord injured patients.

Authors:  M Invernizzi; S Carda; M Rizzi; E Grana; D F Squarzanti; C Cisari; C Molinari; F Renò
Journal:  Spinal Cord       Date:  2015-04-21       Impact factor: 2.772

2.  Reduced mitochondrial lipid oxidation leads to fat accumulation in myosteatosis.

Authors:  Jonathan P Gumucio; Austin H Qasawa; Patrick J Ferrara; Afshan N Malik; Katsuhiko Funai; Brian McDonagh; Christopher L Mendias
Journal:  FASEB J       Date:  2019-04-02       Impact factor: 5.191

3.  The relationship between pressure offloading and ischial tissue health in individuals with spinal cord injury: An exploratory study.

Authors:  Sharon Gabison; Sunita Mathur; Ethne L Nussbaum; Milos R Popovic; Mary C Verrier
Journal:  J Spinal Cord Med       Date:  2019-10       Impact factor: 1.985

4.  Potentially inappropriate medications are negatively associated with functional recovery in patients with sarcopenia after stroke.

Authors:  Ayaka Matsumoto; Yoshihiro Yoshimura; Fumihiko Nagano; Sayuri Shimazu; Ai Shiraishi; Yoshifumi Kido; Takahiro Bise
Journal:  Aging Clin Exp Res       Date:  2022-08-29       Impact factor: 4.481

5.  Stroke and sarcopenia.

Authors:  Manuel F Mas; Javier González; Walter R Frontera
Journal:  Curr Phys Med Rehabil Rep       Date:  2020-09-15

6.  Unaffected arm muscle hypercatabolism in dysphagic subacute stroke patients: the effects of essential amino acid supplementation.

Authors:  Roberto Aquilani; Mirella Boselli; Giuseppe D'Antona; Paola Baiardi; Federica Boschi; Simona Viglio; Paolo Iadarola; Evasio Pasini; Annalisa Barbieri; Maurizia Dossena; Andria Innocenza Bongiorno; Manuela Verri
Journal:  Biomed Res Int       Date:  2014-11-09       Impact factor: 3.411

Review 7.  Sarcopenia and neurosurgery.

Authors:  Seung Won Park
Journal:  J Korean Neurosurg Soc       Date:  2014-08-31

8.  Inflammatory Mechanisms Associated with Skeletal Muscle Sequelae after Stroke: Role of Physical Exercise.

Authors:  Hélio José Coelho Junior; Bruno Bavaresco Gambassi; Tiego Aparecido Diniz; Isabela Maia da Cruz Fernandes; Érico Chagas Caperuto; Marco Carlos Uchida; Fabio Santos Lira; Bruno Rodrigues
Journal:  Mediators Inflamm       Date:  2016-08-28       Impact factor: 4.711

9.  Effects of inclined treadmill walking training with rhythmic auditory stimulation on balance and gait in stroke patients.

Authors:  Sung Kyeung Yoon; Soon Hee Kang
Journal:  J Phys Ther Sci       Date:  2016-12-27

10.  Rehabilitation nutrition for sarcopenia with disability: a combination of both rehabilitation and nutrition care management.

Authors:  Hidetaka Wakabayashi; Kunihiro Sakuma
Journal:  J Cachexia Sarcopenia Muscle       Date:  2014-09-16       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.